As automation biology, hardware, and AI intersect, the vision of fully autonomous, self-driving labs is moving from science fiction to reality. This session explores the cutting-edge convergence of artificial intelligence, robotics, and synthetic biology—unlocking a future where biological workflows are continuously developed, executed, and optimized without human intervention. Join leading voices at the forefront of lab automation and AI-driven experimentation as they discuss the infrastructure, algorithms, and design principles required to build self-driving laboratories.

In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.

This panel will bring together leaders across industry, public sector and the community to examine the systemic barriers slowing the bioeconomy’s growth and ask, “What best practices are we seeing to unlock progress?” Despite breakthroughs in synbio—including recent our findings showing 96% of businesses are advancing biosolutions—progress remains stalled by discovery costs, scaling challenges, regulatory uncertainty, and investment bottlenecks. Join this session to understand how these challenges are being overcome to ensure synbio moves from future predictions to large-scale impact. The discussion will focus on tangible actions to accelerate this transition and realize the full economic promise of the bioeconomy.